Table 2.
Rifapentine Pharmacokinetic Results in IMPAACT 2001 and Other Studies in Nonpregnant Populations
| Rifapentine Parameter | IMPAACT 2001 (n = 50) | Weiner, JPIDS 2014 [16] (n = 80) |
|---|---|---|
| CL/F, L/hour (RSE) | ||
| Antepartuma | ||
| HIV-positive | 1.56 (7%) | … |
| HIV-negative | 1.20 (6%) | … |
| Postpartum | ||
| HIV- positive | 1.60 (11%) | … |
| HIV-negative | 1.53 (8%) | … |
| Nonpregnant (HIV-negative) | … | 2.32 (11%) |
| CLmet/F (RSE) | 2.75 (7%) | 2.05 (10%) |
| Median AUCSS (5th–95th percentile), mg × hour/L | ||
| Antepartuma | ||
| HIV-positive | 522 (359–803) | … |
| HIV-negative | 786 (549–1171) | … |
| Postpartum | ||
| HIV-positive | 554 (434–751) | … |
| HIV-negative | 673 (471–847) | … |
| Nonpregnant (HIV-negative) | … | 553 (326–931) |
| Median (IQR) Cmin, mg/L | 1.05 (0.455–2.01) | … |
| Median (IQR) Cmax, mg/L | 27.4 (24.7–34.6) | … |
Abbreviations: AUCSS, steady-state area under the concentration-time curve; CL/F, clearance; CLmet/F, clearance of metabolite; Cmax, observed maximum concentration; Cmin, observed minimum concentration; IMPAACT, International Maternal Pediatric Adolescent AIDS Clinical Trial Network; IQR, interquartile range; JPIDS, Journal of the Pediatric Infectious Diseases Society; RSE, relative standard error.
aIncludes combined second- and third-trimester data.